↓ Skip to main content

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients

Overview of attention for article published in Leukemia, March 2009
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (90th percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

patent
19 patents
wikipedia
8 Wikipedia pages

Readers on

mendeley
88 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients
Published in
Leukemia, March 2009
DOI 10.1038/leu.2009.50
Pubmed ID
Authors

A Pardanani, T Lasho, G Smith, C J Burns, E Fantino, A Tefferi

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 88 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 1%
United States 1 1%
Belgium 1 1%
Unknown 85 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 25 28%
Student > Ph. D. Student 13 15%
Other 6 7%
Student > Doctoral Student 6 7%
Professor > Associate Professor 5 6%
Other 19 22%
Unknown 14 16%
Readers by discipline Count As %
Agricultural and Biological Sciences 26 30%
Biochemistry, Genetics and Molecular Biology 15 17%
Medicine and Dentistry 13 15%
Chemistry 8 9%
Pharmacology, Toxicology and Pharmaceutical Science 4 5%
Other 6 7%
Unknown 16 18%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 October 2023.
All research outputs
#2,947,680
of 26,017,215 outputs
Outputs from Leukemia
#758
of 5,566 outputs
Outputs of similar age
#9,641
of 113,003 outputs
Outputs of similar age from Leukemia
#4
of 35 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,566 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.7. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 113,003 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 35 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.